drugset
drugset / Trial / NCT07028697

A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

NCT07028697 ↗

Phase 3 Completed 164 enrolled Nxera Pharma Korea Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase 3 study is to evaluate the efficacy and safety of Daridorexant compared to in participants with insomnia disorder.

Timeline

Start
2024-12-04
Primary completion
2025-09-23
Completion
2025-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule — Oral

Indications

insomnia